Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FREE-002
- Development stage
- Unknown
- Lead developer
- Freedom Biosciences
- Modality
- Small Molecules
01
Overview
**FREE-002** is an investigational ketamine-based neuropsychiatric therapeutic program developed by Freedom Biosciences for **comorbid major depressive disorder and substance use disorder**. The program is intended to preserve ketamine-associated antidepressant activity while reducing addiction liability. Freedom Biosciences' public pipeline places FREE-002 in Phase 2 and identifies it as one of the company's clinical-data-supported programs. The precise composition, formulation, route of administration, and mechanism beyond its ketamine-based pharmacology have not been publicly disclosed.
- Other names
- Reduced Addiction Liability Ketamine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on FREE-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FREE-002.